Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →J&J sees value beyond lead prostate cancer program in $3B Halda takeout. While Halda's prostate cancer program clearly motivated the acquisition, J&J appears…
J&J's $3B Halda Acquisition Brings a Way to Overcome Drug Resistance in Prostate Cancer. Halda's innovative technology is designed to work even when cancers no…
J&J announced the successful completion of its acquisition of Halda Therapeutics OpCo, Inc. for $3.05B in cash (Dec 29, 2025).
Source summaries from our enrichment pipeline; follow links for originals.
All 13 sources with sentiment breakdown →
Johnson & Johnson (NYSE: JNJ) completed its acquisition of Halda Therapeutics OpCo, Inc. on December 29, 2025 for $3.05 billion in cash, having announced the definitive agreement on November 17, 2025. The deal brings J&J Halda's proprietary RIPTAC (Regulated Induced Proximity TArgeting Chimera) platform for oral, targeted solid-tumor therapies and its lead asset HLD-0915, a once-daily oral RIPTAC in a Phase 1/2 trial for metastatic castration-resistant prostate cancer (mCRPC). First-in-human data reported in October 2025 showed HLD-0915 was well tolerated with encouraging anti-tumor activity — among 22 patients completing ≥2 cycles, 59% achieved a PSA50 response and 32% a PSA90 response, alongside ctDNA reductions. J&J expects to accelerate the ongoing Phase 1/2 study (primary completion targeted March 2027) and extend RIPTAC into additional solid tumors.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Johnson & Johnson / Halda Therapeutics, Inc. (this deal) | 2025 | $3.0B | — |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $9.0B | 96 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Johnson & Johnson / Cougar Biotechnology, Inc. | 2009 | $970M | 91 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Johnson & Johnson / Aragon Pharmaceuticals Inc. | 2013 | $1.0B | 89 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $350M | 83 |
← Browse all deals · How we score deals
More: 2025 deals · Johnson & Johnson deals · Oncology deals